Observational studyGut2026
Characteristics of an antibody profile associated with protection against hepatitis C virus reinfection in a high-risk cohort.
Observational study in Gut, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Progress in clinical research related to viral hepatitis in 2025].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWithout a vaccine, HCV (re)infections continue to afflict individuals at high risk, for example, men who have sex with men (MSM).
objectiveTo guide vaccine development, we assessed whether natural protection against observed HCV reinfection among MSM was associated with a distinct humoral immune profile.
designFrom a prospective cohort of HIV-positive MSM with acute HCV infection (MOSAIC, Dutch MSM Observational Study of Acute Infection with hepatitis C), we selected 13 cases who became HCV-reinfected (R) and 18 controls who remained free of observed reinfections (non-reinfected, NR) in 0.5-9.5 years after primary infection clearance, matched for calendar year of primary infection. At time point T
resultsHCV-neutralising responses were observed mainly at T
conclusionWe propose broad, potent serum Fc-mediated effector functions and neutralisation and a broad anti-E1E2 antibody epitope specificity as ingredients of HCV-protective immunity towards which vaccination approaches should aim.
Indexed as
Identifiers
41136184What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.